Abstract:Background: Previous studies focused more on the short-term risk of cardiovascular (CV) death due to traumatic psychological stress after a cancer diagnosis and the acute cardiotoxicity of anticancer treatments than on the long-term risk of CV death. Methods: Time trends in the proportions of CV death (P CV ), cancer death (P CA ), and other causes in deaths from all causes were used to show preliminary relationships among the three causes of death in 4,806,064 patients with cancer from the Surveillance, Epidemiology, and End Results (SEER) program. Competing mortality risk curves were used to investigate when the cumulative CV mortality rate (CMR CV ) began to outweigh the cumulative cancer mortality rate (CMR CA ) for patients with cancer who survived for more than 10 years. Multivariable competing risk models were further used to investigate the potential factors associated with CV death. Results: For patients with cancer at all sites, the P CV increased from 22.8% in the 5th year after diagnosis to 31.0% in the 10th year and 35.7% in the 20th year, while the P CA decreased from 57.7% in the 5th year after diagnosis to 41.2 and 29.9% in the 10th year and 20th year, respectively. The P CV outweighed the P CA (34.6% vs. 34.1%) since the 15th year for patients with cancer at all sites, as early as the 9th year for patients with colorectal cancer (37.5% vs. 33.2%) and as late as the 22nd year for patients with breast cancer (33.5% vs. 30.6%). The CMR CV outweighed the CMR CA since the 25th year from diagnosis. Multivariate competing risk models showed that an increased risk of CV death was independently associated with older age at diagnosis [hazard ratio and 95% confidence intervals [HR (95%CI)] of 43.39 (21.33, 88.28) for ≥ 80 vs. ≤ 30 years] and local metastasis [1.07 (1.04, 1.10)] and a decreased risk among women [0.82 (0.76, 0.88)], surgery [0.90 (0.87, 0.94)], and chemotherapy [0.85 (0.81, 0.90)] among patients with cancer who survived for more than 10 years. Further analyses of patients with cancer who survived for more than 20 years and sensitivity analyses by cancer at all sites showed similar results. Conclusion: CV death gradually outweighs cancer death as survival time increases for most patients with cancer. Both the cardio-oncologist and cardio-oncology care should be involved to reduce CV deaths in long-term cancer survivors.

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism

Analysis of Cardiovascular Diseases Affecting the Diagnosis and Treatment of Cancer Patients

Cardiovascular health of patients with cancer: Challenges abound

Analysis of Epidemiological Characteristics of New Cardiovascular Diseases in Cancer Patients with Cardiovascular Disease

Cancer as a Risk Factor for Cardiovascular Disease

Breast cancer and cardiovascular health

Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms

Evolving data on cardiovascular complications in cancer

Coronary atherosclerosis and chemotherapy: From bench to bedside

Genetic factors in the pathogenesis of cardio-oncology

Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors

Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment

Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1

CVD phenotyping in oncologic disorders: cardio-miRNAs as a potential target to improve individual outcomes in revers cardio-oncology

Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights

Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology

Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation